Scientists are launching a nationwide trial to evaluate whether the weight-loss drug Zepbound can alleviate long Covid symptoms. The study focuses on the drug's anti-inflammatory properties. Tirzepatide, Zepbound's active ingredient, has already shown benefits in reducing risks of cardiovascular and chronic kidney diseases beyond weight loss.
Obesity medications like Wegovy and Zepbound have gained attention for their ability to help people lose weight while also lowering the risk of cardiovascular disease and chronic kidney disease. Now, researchers are exploring new applications for these GLP-1 drugs, which are being studied for a wide range of conditions.
A US-wide clinical trial will specifically test tirzepatide, the key component in Zepbound, as a potential treatment for long Covid. Long Covid refers to persistent symptoms following a Covid-19 infection, and the trial aims to determine if the drug's anti-inflammatory effects can help ease these lingering issues.
This development builds on the growing evidence of GLP-1 drugs' broader health impacts. While primarily approved for weight management, their potential in addressing inflammation-related conditions like long Covid could expand treatment options for millions affected by the pandemic's aftermath.
The trial's initiation marks another step in repurposing these 'wonder drugs' for unmet medical needs, though results are pending and further research is needed to confirm efficacy.